Cadrenal Therapeutics, Inc. (CVKD)

NASDAQ: CVKD · Real-Time Price · USD

7.40

-0.24 (-3.14%)

Jan 23, 2026, 11:46 AM EST - Market open

Cadrenal Therapeutics Employees

Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.

Employees

4

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$3,596,410

Market Cap

17.30M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2024	4	0	-
Dec 31, 2023	4	1	33.33%
Dec 31, 2022	3	-	-

Related Stocks

Company Name	Employees
CollPlant Biotechnologies	57
KALA BIO	38
Lisata Therapeutics	26
Citius Pharmaceuticals	23
OSR Holdings	21
VYNE Therapeutics	13
Iterum Therapeutics	9
ProMIS Neurosciences	8

Employee Rankings

CVKD News

11 days ago - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor - GlobeNewsWire
24 days ago - Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - Accesswire
25 days ago - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - Accesswire
5 weeks ago - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - GlobeNewsWire
6 weeks ago - Cadrenal's Quiet Expansion Play Is Starting to Get Loud - Accesswire
6 weeks ago - Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market - Accesswire
6 weeks ago - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - GlobeNewsWire
7 weeks ago - Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - GlobeNewsWire